Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ARYx Therapeutics Inc.

www.aryx.com

Latest From ARYx Therapeutics Inc.

Armetheon raises $7m to revive ARYx's Phase III anticoagulant

A four-years-delayed Phase III clinical trial for the oral anticoagulant (OAC) tecarfarin is back on track now that Menlo Park, California-based Armetheon has raised a $7m Series A venture capital round to back what it sees as a better alternative to the standard of care, warfarin.

FDA May Ease Up On CV Safety Requirements For GI Motility Drugs Compared To Diabetes, Obesity

Developers of 5-HT4 agonists should not be required to conduct dedicated cardiovascular studies, despite the safety concerns raised by two previously approved products in the class, an FDA advisory committee said.

BioPharmaceutical United States

VC-backed GI Start-Ups See Opportunity In IBS

Private companies developing drugs for gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome hope to take advantage of a resurging interest in the space after linaclotide developer Ironwood Pharmaceuticals has shown its novel, locally acting guanylate cyclise type-C agonist is efficacious in four Phase III trials. We profile four such hopefuls in this issue: Altheus Therapeutics, AltheRx Pharmaceuticals, Aldrex and Second Genome.

BioPharmaceutical

GI Motility Agents Do Not Need Dedicated CV Safety Studies, Panel Says

FDA’s Gastrointestinal Drugs Advisory Committee overwhelmingly opposes CV-specific studies for the class of 5-HT4 receptor agonists, but says Phase III trials should include patients at high risk for events.

BioPharmaceutical Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ARYx Therapeutics Inc.
  • Senior Management
  • Paul Goddard, PhD, Chmn. & CEO
    John Varian, COO
    Daniel M Canafax, VP, Chief Dev. Officer
  • Contact Info
  • ARYx Therapeutics Inc.
    Phone: (510) 585-2200
    6300 Dumbarton Cir.
    Freemont, CA 94555
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register